GemVax Group is making remarkable progress in manufacturing semiconductors and other equipment filters, pharmaceuticals, mobile solutions, and fashion businesses. GemVax&KAEL will become a leading company in the 4th Industrial Revolution era by achieving innovative technology development in the bio and life sciences field.
GemVax&KAEL is developing new drugs for Alzheimer’s Disease, Benign Prostatic Hyperplasia, Pancreatic Cancer, etc. Its clinical trials are in progress in Korea, USA, etc. Below are the vision for GemVax&KAEL.
Since 1989, we have continued our efforts to improve the quality of human life through various clinical trials.
Received the Best Academic Award of the Korean Society of Prostate Prevention for GV1001 Benign Prostatic Hyperplasia Phase II Clinical Trial
Presented GV1001 Benign Prostatic Hyperplasia Phase II Clinical Trial result at European Association Urology (EAU)
Published GV1001 Benign Prostatic Hyperplasia Phase II Clinical Trial thesis on BJU International
Finished patient recruiting for Phase III Clinical Trial of GV1001 Pancreatic Cancer (Korea)
Finished patient recruiting for Phase II Clinical Trial of GV1001 Alzheimer’s Disease (Korea)
IND approval for Phase III Clinical Trial of GV1001 Benign Prostatic Hyperplasia (Korea)
IND approval for Phase II Clinical Trial of GV1001 Alzheimer’s Disease (USA)
Presented GV1001 Alzheimer’s Disease Phase II Clinical Trial result at CTAD Society (USA San Diego).
Presented GV1001 Alzheimer’s Disease Phase II Clinical Trial result at Korean Society of Dementia
Selected for Research and Development Project for Overcoming Dementia (GV1001)
Published GV1001 Benign Prostatic GV1001 Alzheimer’s Disease Phase II Clinical Trial thesis on Alzheimer’s Research & Therapy
Presented GV1001 Pancreatic Cancer Phase III Clinical Trial result at ASCO (USA)
Finished patient recruiting for Phase II Clinical Trial of GV1001 Benign Prostatic Hyperplasia (Korea)
IND approval for Phase III Clinical Trial of GV1001 Alzheimer’s Disease (Korea)
Initiated GV1001 Alzheimer’s Disease Phase II Clinical Trial (USA)
Finished patient recruiting for Phase II Clinical Trial of GV1001 Benign Prostatic Hyperplasia (Korea)
IND approval for Phase II Clinical Trial of GV1001 Alzheimer’s Disease (Korea)
Research agreement with KDDF (Korea Drug Development Fund) on GV1001 for Alzheimer’s Disease treatment
Finished Phase II Clinical Trial of GV1001 Benign Prostatic Hyperplasia (Korea)
Initiated Phase II Clinical Trial of GV1001 Alzheimer’s Disease (Korea)
Presented GV1001 Benign Prostatic Hyperplasia Phase II Clinical Trial result at APPS
Awarded at the Small Business IP Management Competition
Submitted IND application for Phase III Clinical Trial of GV1001 Prostate Cancer (Korea)
IND approval for Phase III Clinical Trial of GV1001 Prostate Cancer (Korea)
Signed a contract to transfer management rights of Samsung Pharmaceutical Co., Ltd.
Presented the correlation between GV1001 and biomarker at 2014 ASCO
Approved NDA for Pancreatic Cancer immuno-cancer treatment, RIAVAX
Submitted IND application for Phase II Clinical Trial of GV1001 Benign Prostatic Hyperplasia (Korea)
Won the Best New Drug Award (Ministry of Food and Drug Safety)
Certified as Innovative Pharmaceutical Company (Ministry of Foods and Drug Safety / KOREA)
IND approval for Phase II Clinical Trial of GV1001 Benign Prostatic Hyperplasia (Korea)
GemVax & KAEL Co., Ltd. Absorption-type Merger of KAEL GemVax Co., Ltd.
Submitted IND application for Phase III Clinical Trial of GV1001 Pancreatic Cancer (Korea)
IND approval for Phase III Clinical Trial of GV1001 Pancreatic Cancer (Korea)
Samsung Pharmaceutical Co., Ltd. signed a domestic license agreement for RIAVAX
Certified as Venture Company.
Established Kael GemVax Co., Ltd.
Acquisition of GemVax AS from Pharmexa AS.
Acquisition of Epimmune Inc (DNA vaccine development company for infectious Diseases in the USA)
Changed name from KAEL Co., Ltd to GemVax & KAEL Co., Ltd
Presented GV1001 TeloVac Clinical Trial result at 2013 ASCO
Submitted NDA application for GV1001 Pancreatic Cancer immuno-cancer treatment (Korea)
Established GV1001 Research Foundation
Professor Gustav Gaudernack’s collaborative study on the development of anti-cancer immunotherapy (Norway radium Hospital Research)
Research and Development of telomerase derived peptide Immuno-Cancer Treatment
Initiated Phase 1/2 Clinical Trial of GV1001 Pancreatic Cancer (CTN1/2000)
Initiated Phase 1/2 Clinical Trial of GV1001 Melanoma (hTERT-1/01)
Initiated Phase 1/2 Clinical Trial of GV1001 Non-Small Cell Lung Cancer (CTN3/2000)
Founded GemVax AS, a vaccine specialized company (Norway)
Initiated Phase 1/2 Clinical Trial of GV1001 Pancreatic Cancer (CTN7/2003)
Initiated Phase II Clinical Trial of GV1001 Pancreatic Cancer (CTN6/2003)
Initiated Phase II Clinical Trial of GV1001 Melanoma (PO3700)
Initiated Phase 1/2 Clinical Trial of GV1001 Pancreatic Cancer (CTN4/2003)
Initiated Phase III Clinical Trial of GV1001 Pancreatic Cancer (Primovax)
Selected as Orphan Drug (FDA & EMA)
Initiated Phase II Clinical Trial of GV1001 Liver Cancer (HeptoVax)
Initiated Phase II Clinical Trial of GV1001 Non-Small Cell Lung Cancer (CTN8/2006)
Initiated Phase III Clinical Trial of GV1001 Pancreatic Cancer (TeloVac, UK)
A compound composed of two or more amino acids with a peptide bond (-NH-CO-). It is the most important substance in the human body and has various functions and structures at the same time.
GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT).
It is a DNA-protein structure located at the end of the chromosome prevents damage to the chromosome. Telomeres become shorter each time a cell splits. Without telomeres, fatal damage to the cell occurs. Telomerase is an enzyme that inhibits the shortening of telomeres due to cell division.
Elizabeth H. Blackburn, Jack W, Szostak, and Carol W. Greider were awarded the Nobel Prize in Physiology of Medicine for discovering the chromosomal protection mechanisms of telomeres and telomerase in 2009.
A compound composed of two or more amino acids with a peptide bond (-NH-CO-). It is the most important substance in the human body and has various functions and structures at the same time.
GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT).
It is a DNA-protein structure located at the end of the chromosome prevents damage to the chromosome. Telomeres become shorter each time a cell splits. Without telomeres, fatal damage to the cell occurs. Telomerase is an enzyme that inhibits the shortening of telomeres due to cell division.
Elizabeth H. Blackburn, Jack W, Szostak, and Carol W. Greider were awarded the Nobel Prize in Physiology of Medicine for discovering the chromosomal protection mechanisms of telomeres and telomerase in 2009.
Several research results have been applied and registered for domestic and foreign patents to secure intellectual property rights. Their research achievements are recognized by being published in renowned international academic journals.
Several research results have been applied and registered for domestic and foreign patents to secure intellectual property rights. Their research achievements are recognized by being published in renowned international academic journals.
Besides cancer, various indications such as Benign Prostatic Hypertrophy and Alzheimer’s Disease have confirmed the additional effects of GV1001, such as anti-inflammatory, antioxidant, and hormonal regulatory effects.
